Claims for Patent: 10,363,214

Summary for Patent: 10,363,214

Title:	Method for treating atrophic age related macular degeneration
Abstract:	Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
Inventor(s):	Whitcup; Scott M. (Laguna Hills, CA), Robinson; Michael R. (Irvine, CA), Blanda; Wendy M. (Tustin, CA), Hughes; Patrick M. (Aliso Viejo, CA), Burke; James A. (Santa Ana, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	14/324,630
Patent Claims:	1. A method for treatment of dry age-related macular degeneration the method comprising the steps of: preparing a biocompatible, sustained release drug delivery system comprising between 5 .mu.g and 20 .mu.g of bevacizumab and a polymeric hyaluronic acid vehicle cross-linked or noncross-linked the bevacizumab; and injecting the drug delivery system into the vitreous of an eye of a patient with dry AMD; wherein the drug delivery system releases between about 14 ng to about 120 ng of bevacizumab over a 24 hour period for between about 3 months and about 6 months. 2. The method of claim 1, wherein the drug delivery system has a viscosity of between about 130,000 cps and about 300,000 cps at a shear rate of about 0.1 second at about 25.degree. C. 3. The method of claim 1, wherein the drug delivery system is injected using a 25 to 30 gauge syringe. 4. The method of claim 1, wherein the non-injected eye of the patient has wet AMD. 5. The method of claim 1, wherein the dry AMD eye is treated by preventing or delaying the onset of retinal neovascularization in the dry AMD eye. 6. The method of claim 1, further comprising a second polymeric component in the polymeric hyaluronic acid vehicle, the second polymeric component is selected from the group consisting of a polymeric lactic acid, a polymeric glycolic acid, a lactic acid-glycolic acid copolymer, a polymeric hydroxypropylmethylcellulose and mixtures thereof. 7. The method of claim 1, wherein the bevacizumab is homogeneously distributed throughout the polymeric hyaluronic acid vehicle. 8. The method of claim 1, wherein the polymeric hyaluronic acid is a cross-linked hyaluronic acid. 9. The method of claim 1, wherein the polymeric hyaluronic acid is a noncross-linked hyaluronic acid. 10. The method of claim 1, wherein the polymeric hyaluronic acid has a molecular weight between about 1 million Daltons and about 2 million Daltons. 11. The method of claim 1 wherein the bevacizumab is entrapped within the polymeric hyaluronic acid vehicle. 12. The method of claim 11 wherein the hyaluronic acid vehicle comprises microspheres. 13. The method of claim 11 wherein the hyaluronic acid vehicle is a solid implant. 14. The method of claim 11 wherein the hyaluronic acid is selected from the group consisting of cross-linked hyaluronic acid, noncross-linked hyaluronic acid and mixtures thereof.

Details for Patent 10,363,214

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2028-07-18